A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel,

ID Number 15-0284

Principal Investigator(s)
Matthew Galsky

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to:

  • Test the safety of the research study drug, pembrolizumab (also called MK-3475)
  • Test the effectiveness of the research study drug pembrolizumab compared to paclitaxel or docetaxel or vinflunine for recurrent/progressive metastatic urothelial cancer.

This is a research study to test an investigational drug that has been FDA approved for use in certain types of melanoma, however it has not been approved for your type of cancer, urothelial cancer.  You are being offered the opportunity to take part in this study because you have urothelial cancer that has either recurred or progressed in spite previous therapy with a platinum-containing chemotherapy regimen.  Subjects in this study will be assigned by chance to receive either the investigational study drug, pembrolizumab or either paclitaxel or decetaxel.

Contact Information
Kiev Gimpel-Tetra

Recruiting Patients: No